Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR(+) Triple Negative Breast Cancer

NCT02750358 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT02750358
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02750358 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR(+) Triple Negative Breast Cancer
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
May 19, 2016
Completion date
May 31, 2027
Enrollment
50 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, early stage, triple negative breast cancer